Patient characteristics and treatment information
| Patient . | Weight at NPP start, kg . | Additional hematologic diagnosis . | Concomitant treatment . | No. of infusions . | Duration of NPP participation, mo . | Highest dose received . | Breakthrough on highest dose . |
|---|---|---|---|---|---|---|---|
| 001 | 57 | LPL with CAS, active NHL | Ibrutinib | 6 | 2 | 3420 mg (60 mg/kg) | Yes |
| 002 | 75 | CAD/cancer | EPO (5000 IU 3 times per wk), rituximab | 11 | 5 | 4500 mg (60 mg/kg) | No |
| 003 | 63 | NA | NA | 9 | 3.5 | 3960 mg (60 mg/kg) | Yes |
| 004 | 75 | NA | Rituximab | 13 | 5.5 | 5.5 g | No |
| 005 | 60 | CAD after LPL | NA | 43 | 20 | 5.5 g | No |
| 006 | 75 | Mixed AIHA | NA | 43 | 20 | 5.5 g | No |
| 007 | 78 | CAD after LPL | EPO (10 000 IU 3 times per wk) | 20 | 9.5 | 5.5 g | No |
| Patient . | Weight at NPP start, kg . | Additional hematologic diagnosis . | Concomitant treatment . | No. of infusions . | Duration of NPP participation, mo . | Highest dose received . | Breakthrough on highest dose . |
|---|---|---|---|---|---|---|---|
| 001 | 57 | LPL with CAS, active NHL | Ibrutinib | 6 | 2 | 3420 mg (60 mg/kg) | Yes |
| 002 | 75 | CAD/cancer | EPO (5000 IU 3 times per wk), rituximab | 11 | 5 | 4500 mg (60 mg/kg) | No |
| 003 | 63 | NA | NA | 9 | 3.5 | 3960 mg (60 mg/kg) | Yes |
| 004 | 75 | NA | Rituximab | 13 | 5.5 | 5.5 g | No |
| 005 | 60 | CAD after LPL | NA | 43 | 20 | 5.5 g | No |
| 006 | 75 | Mixed AIHA | NA | 43 | 20 | 5.5 g | No |
| 007 | 78 | CAD after LPL | EPO (10 000 IU 3 times per wk) | 20 | 9.5 | 5.5 g | No |
CAS, cold agglutinin syndrome; EPO, erythropoietin; NA, not applicable; NHL, non-Hodgkin lymphoma.